Similar articles

• Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): rationale and study design.

  Imai E, Ito S, Haneda M, Chan JC, Makino H; ORIENT Investigators. Imai E, et al. Hypertens Res. 2006 Sep;29(9):703-9. doi: 10.1291/hypres.29.703. Hypertens Res. 2006. PMID: 17249526 Clinical Trial.
• Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.

  Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda M, Makino H; ORIENT study investigators. Imai E, et al. Diabetologia. 2011 Dec;54(12):2978-86. doi: 10.1007/s00125-011-2325-z. Epub 2011 Oct 13. Diabetologia. 2011. PMID: 21993710 Free PMC article. Clinical Trial.
• Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension).

  Imai E, Haneda M, Yamasaki T, Kobayashi F, Harada A, Ito S, Chan JC, Makino H. Imai E, et al. Hypertens Res. 2013 Dec;36(12):1051-9. doi: 10.1038/hr.2013.86. Epub 2013 Sep 12. Hypertens Res. 2013. PMID: 24026038 Free PMC article. Clinical Trial.
• Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.

  Chatzikyrkou C, Menne J. Chatzikyrkou C, et al. Expert Rev Cardiovasc Ther. 2012 Sep;10(9):1087-92. doi: 10.1586/erc.12.100. Expert Rev Cardiovasc Ther. 2012. PMID: 23098143 Review.
• [Primary cardiorenal prevention in patients with type-2 diabetes. The Roadmap study].

  Halimi S. Halimi S. Presse Med. 2005 Oct 22;34(18):1300-2. doi: 10.1016/s0755-4982(05)84177-6. Presse Med. 2005. PMID: 16269993 Review. French.